Publications by authors named "Gerard Suris"
Background: The usefulness of thiopurines has been poorly explored in pouchitis and other pouch disorders.
Objective: To evaluate the effectiveness and safety of azathioprine as maintenance therapy in inflammatory pouch disorders.
Design: This was a retrospective and multicentre study.
Article Synopsis
- Infliximab is considered the most effective anti-TNF treatment for ulcerative colitis (UC), but there is limited information on its use as a second anti-TNF option.
- This study analyzed 473 UC patients to compare outcomes between those receiving their first anti-TNF treatment via intravenous (IV) versus subcutaneous (SC) routes.
- Results showed similar clinical response and remission rates after 14 and 52 weeks, suggesting that while a second anti-TNF can be effective, prior failure of the first anti-TNF significantly impacts long-term success.
Background And Objectives: There are few scales with prospective validation for the assessment of the upper gastrointestinal mucosal cleanliness during an esophagogastroduodenoscopy (EGD). The aim of this study was to develop a valid and reproducible cleanliness scale for use during an EGD.
Methods: We developed a cleanliness scale (Barcelona scale) with a score (0-2 points) of five segments of the upper gastrointestinal tract with thorough cleaning techniques (esophagus, fundus, body, antrum, and duodenum).
(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case−control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March−July 2020 included in the ENEIDA of GETECCU.
View Article and Find Full Text PDFIntroduction: The prevalence of penetrating complications in Crohn's disease (CD) increases progressively over time, but evidence on the medical treatment in this setting is limited. The aim of this study was to evaluate the effectiveness of biologic agents in CD complicated with internal fistulizing disease.
Methods: Adult patients with CD-related fistulae who received at least 1 biologic agent for this condition from the prospectively maintained ENEIDA registry were included.
Article Synopsis
- A study examined the effectiveness of biologic early prophylaxis for preventing endoscopic post-operative recurrence (ePOR) in Crohn's disease patients after ileocecal resection (ICR).
- It included 297 patients and found that ePOR occurred in about 41.8% of cases within one year, with varying rates across treatment groups: 40.2% for anti-TNF, 33% for vedolizumab (VDZ), and 61.8% for ustekinumab (UST).
- The results indicated no significant differences in ePOR risk between the anti-TNF therapy and the other biologics after adjusting for patient factors, suggesting early prevention was effective for around 60% of patients regardless of
Background And Aims: Crohn's disease [CD] can develop penetrating complications at any time during the disease course. Enterocutaneous fistulae [ECF] are disease-related complications with an important impact on quality of life. Our aim was to describe the outcomes of this complication, including its medical and/or surgical management and their temporal trends.
View Article and Find Full Text PDFNationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry.
J Clin Med
January 2022
We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia).
View Article and Find Full Text PDFArticle Synopsis
- This study looked into how well two medications, ustekinumab (UST) and vedolizumab (VDZ), work as third-line treatments for patients with Crohn's disease who haven’t responded well to other medications.
- Researchers included 204 patients, with 76% receiving VDZ followed by UST, and 24% the opposite. After 16 to 22 weeks, about half of patients in both groups showed a response to the treatment.
- By week 52, similar response rates (around 86%) were observed, with about a quarter to a third of patients attaining clinical remission, indicating that both medications were similarly effective as third-class therapies. *
Introduction: The pandemic caused by the SARS-CoV-2 virus has had a serious impact on the functioning of gastrointestinal endoscopy Units. The Asociación Española de Gastroenterología (AEG) and the Sociedad Española de Endoscopia Digestiva (SEED) have proposed the EPAGE guidelines for managing postponed colonoscopies.
Objective: To evaluate the EPAGE guidelines as a management tool compared to the immunologic faecal occult blood test (iFOBT) and compared to risk score (RS) that combines age, sex and the iFOBT for the detection of colorectal cancer (CRC) and significant bowel disease (SBD).
Aim: To evaluate the effectiveness and safety of tofacitinib in ulcerative colitis [UC] in real life.
Methods: Patients from the prospectively maintained ENEIDA registry and treated with tofacitinib due to active UC were included. Clinical activity and effectiveness were defined based on Partial Mayo Score [PMS].
Background: Data on the long-term administration of ustekinumab in recommended doses are limited.
Aim: To assess the real-world, long-term effectiveness of ustekinumab in refractory Crohn's disease (CD).
Methods: Multi-centre study of CD patients starting ustekinumab at the recommended dose, followed for 1 year.